HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

With $97M, Latus pursues a different kind of Huntington’s gene therapy

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

By BioPharma Dive · May 4, 2026 · via BioPharma Dive
With $97M, Latus pursues a different kind of Huntington’s gene therapy

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive

Tags
moneyformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
MoneyFiercePharma ↗
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star hear…
May 5, 2026
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
MoneyBriefing
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
May 3, 2026
Moderna sees revenue bump from international COVID vaccine sales
MoneyBioPharma Dive ↗
The company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turna…
May 1, 2026